Free Trial
NASDAQ:VERU

Veru Q4 2023 Earnings Report

Veru logo
$0.51 -0.01 (-1.56%)
As of 12:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Veru EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Veru Revenue Results

Actual Revenue
$3.86 million
Expected Revenue
$3.95 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Veru Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, December 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Veru's Q2 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Veru Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Unusually active option classes on open March 25th
See More Veru Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email.

About Veru

Veru (NASDAQ:VERU), a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

View Veru Profile

More Earnings Resources from MarketBeat